Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 4/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | ABL2 | P42684 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30484109 | 1.00 | AURKA (0.54) | AURKARETEGFRPDPK1JAK2 | |
| SCHEMBL23852137 | 0.87 | AURKA (0.54) | AURKAEGFRPDPK1JAK2LMNA | |
| SCHEMBL30051967 | 0.82 | PDPK1 (0.50) | RETEGFRPDPK1JAK2GSK3B | |
| SCHEMBL23885373 | 0.82 | PDPK1 (0.50) | RETEGFRPDPK1JAK2GSK3B | |
| SCHEMBL31705976 | 0.81 | AURKA (0.54) | AURKAEGFRLMNAMAPTSMN1; SMN2 | |
| SCHEMBL6881163 | 0.81 | AURKA (0.57) | AURKARETEGFRLMNAMAPT | |
| SCHEMBL6881565 | 0.81 | EGFR (0.44) | RETEGFRPDPK1JAK2GSK3B | |
| SCHEMBL23863268 | 0.77 | AURKA (0.57) | AURKAEGFRLMNAMAPTSMN1; SMN2 | |
| SCHEMBL17204317 | 0.77 | BRD4 (0.43) | PDPK1JAK2BRD4GSK3BERBB2 | |
| SCHEMBL3113184 | 0.77 | AURKA (0.50) | AURKARETEGFRLMNABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378250-B2 | Tricyclic compound as IRAK4 inhibitor | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-08-05 | — | — | US | disclosed |
| EP-3885348-B1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | KOREA RES INST CHEMICAL TECH (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20240366770-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| WO-2023125907-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| US-20220009933-A1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-13 | — | — | US | disclosed |
| EP-3885348-A1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | Korea Research Institute of Chemical Technology (KR) | 2021-09-29 | — | — | EP | disclosed |
| EP-3885348-A1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | Korea Research Institute of Chemical Technology (KR) | 2021-09-29 | — | — | EP | disclosed |
| WO-2011056739-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378250-B2 | Tricyclic compound as IRAK4 inhibitor | IRAK4, IRAK1, IRAK2 | AURKA 738/4885RET 1193/4885EGFR 2885/4885 |
| US-20220009933-A1 | NOVEL TRICYCLIC COMPOUND AS IRAK4 INHIBITOR | IRAK4, IRAK1, IRAK2 | AURKA 808/4885RET 1064/4885EGFR 2862/4885 |
| US-20240366770-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | AURKA 721/4885RET 1135/4885EGFR 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.